Developer docs
API playgroundTry for free, no card

Search company profiles

Ryvu

Full company profile

uuid00055qx

Namestring
Ryvu
Legal namestring
Ryvu Therapeutics S.A.
Websiteurl
ryvu.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical company headquartered in Kraków, Poland, founded in 2007 (formerly Selvita S.A.) and listed on the Warsaw Stock Exchange under ticker RVU. It develops first-in-class small molecule therapies addressing emerging oncology targets, with a portfolio led by romaciclib (RVU120/SEL120), an oral CDK8/19 inhibitor in Phase II for relapsed/refractory acute myeloid leukemia (RIVER-81), myelofibrosis (POTAMI-61) and low-risk MDS (REMARK), and dapolsertib (MEN1703/SEL24), a dual PIM/FLT3 inhibitor in Phase II for diffuse large B-cell lymphoma (JASPIS-01). The preclinical pipeline includes RVU305, a brain-permeable MTA-cooperative PRMT5 inhibitor for MTAP-deleted tumors, alongside STING-based antibody-drug conjugates licensed to Exelixis and an emerging ADC payload program.

The company's discovery engine rests on two proprietary platforms: ONCO Prime, which integrates patient-derived models, engineered systems and high-throughput CRISPR/omics analytics with machine learning to identify synthetic-lethal vulnerabilities in genetically stratified cancers; and PERO, which performs functional validation of structural protein pockets to support rational drug design. A team of roughly 230 employees including 90 PhD holders, supported by an international patent portfolio covering CDK8, MELK, A2A/A2B adenosine receptor and STING agonist chemistries, underwrites the R&D base.

Ryvu is pre-commercial and does not generate product revenue. Operating revenues of EUR 20.7M in FY2025 and EUR 5.1M in Q1 2026 consist of research collaboration reimbursements, clinical milestone payments and non-dilutive grants from European institutions including the European Investment Bank, the Medical Research Agency (ABM), the National Centre for Research and Development (NCBR) and EU regional funds. Strategic commercialization is structured around out-licensing and co-development with major pharma partners — BioNTech (research collaboration extended to November 2028), Exelixis (STING ADCs) and Menarini Group (dapolsertib) — with potential for direct sales upon regulatory approval of romaciclib or other wholly-owned assets.

Short descriptiontext

Ryvu Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule oncology therapies targeting CDK8/19, PIM/FLT3, and PRMT5. Headquartered in Kraków, Poland, it serves patients with hematologic malignancies and solid tumors through wholly-owned and partnered clinical programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersKraków, Poland
HQ citystring
Kraków
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, small molecule therapies, clinical-stage biotechnology, hematologic malignancies, precision oncology
Industry2 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Oncology Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Partnership Revenue
TypeLicensing Royalties
Description

Ryvu generates revenue through research collaborations and licensing agreements with pharmaceutical partners including BioNTech, Exelixis, and Menarini Group. Partners reimburse Ryvu for expenses and the company can receive multiple milestone payments.

ryvu.com
2Grant Funding
TypeManaged Services
Description

Non-dilutive funding from government agencies including European Investment Bank (EUR 22 million venture debt), National Centre for Research and Development (NCBR), Medical Research Agency (ABM), and European Union regional funds. Q1 2026: EUR 5.1 million operating revenues including grants.

ryvu.com
3Clinical Milestones
TypeLicensing Royalties
Description

Revenue recognition from milestones achieved in clinical programs and collaborations, including RVU120 Phase II progress triggering EIB funding disbursement.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1ONCO Prime
Description

Precision oncology discovery platform leveraging patient-driven models, engineered systems, and high-throughput CRISPR/omics analytics for identification of synthetic lethal targets in genetically stratified cancers

ryvu.com
+2 more records
Core offering1 text field

Ryvu Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel small molecule therapies targeting emerging oncology pathways, including CDK8/19, PIM/FLT3, and PRMT5. Its pipeline focuses on hematologic malignancies and selected solid tumors, with drug candidates advancing through preclinical and clinical stages (Phases 1 and 2). The company leverages proprietary discovery platforms to identify first-in-class therapeutic candidates for partnering or further development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 43% CR/CRi rate in RIVER-81 study at recommended dose of 150mg QD romaciclib + venetoclax
+4 more records
Product overview1 text field

Ryvu Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of small molecule oncology therapies with diverse therapeutic mechanisms. The core clinical programs include romaciclib (RVU120), a first-in-class CDK8/19 inhibitor with multiple Phase II trials in hematologic malignancies (RIVER-81 for AML, POTAMI-61 for myelofibrosis, REMARK for LR-MDS), and dapolsertib (MEN1703), a dual PIM/FLT3 kinase inhibitor in Phase II for DLBCL. The preclinical pipeline features RVU305 (MTA-cooperative PRMT5 inhibitor) and early discovery programs in ADCs with novel payloads. Discovery capabilities include the ONCO Prime precision oncology platform for synthetic lethal target identification and the PERO platform for functional target validation.

Product and service1 record
1Romaciclib (RVU120)
Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-16
Description

Research collaboration and exclusive license option agreement originally disclosed in November 2022. In March 2026, the collaboration was extended by one year until November 2028. In September 2025, the collaboration was expanded to support BioNTech in accelerating site activation and patient enrollment for priority oncology clinical programs in Poland including lung, breast, and colorectal cancers. Ryvu supports BioNTech's clinical trials and is reimbursed for expenses with potential for milestone payments.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Collaboration initiated September 2025 as part of MEDWAY project, an investigator-initiated Phase I clinical study evaluating romaciclib in combination with everolimus in children with recurrent or progressive medulloblastoma. First patient first visit expected Q2 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-26
Description

JASPIS-01 Phase II study of dapolsertib (MEN1703/SEL24) for r/r DLBCL is fully funded by Menarini Group and operationally executed by Ryvu. First patient dosed March 2025.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-09-28
Description

Exclusive license agreement with Exelixis for STING ADC technology. Ryvu develops STING-based antibody-drug conjugates for targeted cancer therapy under this partnership.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for REMARK study - Phase II investigator-initiated trial of romaciclib in low-risk MDS. EMSCO provides funding and operational support.

6BCUnited
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for RIVER-81 study in relapsed/refractory AML. BCUnited provides funding and operational support for clinical development.

ryvu.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US clinical-stage oncology biotech developing conditionally activated therapeutics. Comparable as a small-cap clinical-stage oncology company with platform-driven pipeline development.

TypeDirect peer
Description

Clinical-stage UK biotech developing precision oncology therapeutics using bicyclic peptide technology. Comparable as a clinical-stage oncology company advancing novel modalities toward Phase II readouts with partnership revenue.

TypeBroad incumbent
Description

US computational drug discovery platform serving multiple therapeutic areas including oncology. Broader and more established than Ryvu but relevant given overlapping computational/discovery approaches to small molecule design.

TypeEmerging player
Description

US AI-enabled drug discovery company developing pipeline across oncology and rare diseases. Comparable as a technology-driven drug discovery company, though with broader scope and larger capital base.

TypeDirect peer
Description

US clinical-stage oncology biotech targeting chromatin regulatory biology with small molecules. Comparable to Ryvu's transcriptional regulation focus and similar Phase II-stage portfolio profile.

6Syros Pharmaceuticals
TypeDirect peer
Description

US clinical-stage precision oncology biotech using gene regulation platforms to develop small molecule therapies. Comparable in targeting transcriptional dysregulation and hematologic/oncology indications.

TypeDirect peer
Description

US clinical-stage immuno-oncology biotech developing small molecule therapies. Comparable in scale, clinical stage, and oncology small molecule focus.

TypeDirect peer
Description

US clinical-stage oncology biotech developing small molecule therapies targeting dysregulated transcription and cell signaling. Closely comparable to Ryvu's CDK8/19 transcriptional regulation approach and Phase II hematology focus.

TypeDirect peer
Description

US clinical-stage oncology biotech focused on small molecule therapeutics targeting DNA damage response and synthetic lethality. Directly comparable to Ryvu's synthetic lethality and DDR-adjacent pipeline.

TypeDirect peer
Description

Norway-headquartered clinical-stage oncology biotech developing selective kinase inhibitors in hematologic and solid tumors. Highly comparable to Ryvu in size, stage, and kinase-targeting approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment8 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ryvu

Clinical-Stage Oncology Therapeuticsryvu.com

Ryvu Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule oncology therapies targeting CDK8/19, PIM/FLT3, and PRMT5. Headquartered in Kraków, Poland, it serves patients with hematologic malignancies and solid tumors through wholly-owned and partnered clinical programs.

What Ryvu does

Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical company headquartered in Kraków, Poland, founded in 2007 (formerly Selvita S.A.) and listed on the Warsaw Stock Exchange under ticker RVU. It develops first-in-class small molecule therapies addressing emerging oncology targets, with a portfolio led by romaciclib (RVU120/SEL120), an oral CDK8/19 inhibitor in Phase II for relapsed/refractory acute myeloid leukemia (RIVER-81), myelofibrosis (POTAMI-61) and low-risk MDS (REMARK), and dapolsertib (MEN1703/SEL24), a dual PIM/FLT3 inhibitor in Phase II for diffuse large B-cell lymphoma (JASPIS-01). The preclinical pipeline includes RVU305, a brain-permeable MTA-cooperative PRMT5 inhibitor for MTAP-deleted tumors, alongside STING-based antibody-drug conjugates licensed to Exelixis and an emerging ADC payload program.

The company's discovery engine rests on two proprietary platforms: ONCO Prime, which integrates patient-derived models, engineered systems and high-throughput CRISPR/omics analytics with machine learning to identify synthetic-lethal vulnerabilities in genetically stratified cancers; and PERO, which performs functional validation of structural protein pockets to support rational drug design. A team of roughly 230 employees including 90 PhD holders, supported by an international patent portfolio covering CDK8, MELK, A2A/A2B adenosine receptor and STING agonist chemistries, underwrites the R&D base.

Ryvu is pre-commercial and does not generate product revenue. Operating revenues of EUR 20.7M in FY2025 and EUR 5.1M in Q1 2026 consist of research collaboration reimbursements, clinical milestone payments and non-dilutive grants from European institutions including the European Investment Bank, the Medical Research Agency (ABM), the National Centre for Research and Development (NCBR) and EU regional funds. Strategic commercialization is structured around out-licensing and co-development with major pharma partners — BioNTech (research collaboration extended to November 2028), Exelixis (STING ADCs) and Menarini Group (dapolsertib) — with potential for direct sales upon regulatory approval of romaciclib or other wholly-owned assets.

Ryvu firmographics

Firmographics
Name
Ryvu
Legal name
Ryvu Therapeutics S.A.
Website
https://ryvu.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Ryvu Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule oncology therapies targeting CDK8/19, PIM/FLT3, and PRMT5. Headquartered in Kraków, Poland, it serves patients with hematologic malignancies and solid tumors through wholly-owned and partnered clinical programs.
Ownership category
akta.pro rank

Ryvu industry classification

Industry
Product category
Clinical-Stage Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Oncology drug development
  • Small molecule therapies
  • Clinical-stage biotechnology
  • Hematologic malignancies
  • Precision oncology

Where Ryvu is headquartered

Location

Headquarters

HQ city
Kraków
HQ country
Poland
HQ region
Europe

Offices1 record

Markets served

Ryvu business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Partnership Revenue: Ryvu generates revenue through research collaborations and licensing agreements with pharmaceutical partners including BioNTech, Exelixis, and Menarini Group. Partners reimburse Ryvu for expenses and the company can receive multiple milestone payments.
  2. Grant Funding: Non-dilutive funding from government agencies including European Investment Bank (EUR 22 million venture debt), National Centre for Research and Development (NCBR), Medical Research Agency (ABM), and European Union regional funds. Q1 2026: EUR 5.1 million operating revenues including grants.
  3. Clinical Milestones: Revenue recognition from milestones achieved in clinical programs and collaborations, including RVU120 Phase II progress triggering EIB funding disbursement.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Ryvu product offering

Product offering

Core offering

Ryvu Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel small molecule therapies targeting emerging oncology pathways, including CDK8/19, PIM/FLT3, and PRMT5. Its pipeline focuses on hematologic malignancies and selected solid tumors, with drug candidates advancing through preclinical and clinical stages (Phases 1 and 2). The company leverages proprietary discovery platforms to identify first-in-class therapeutic candidates for partnering or further development.

Product overview

Ryvu Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of small molecule oncology therapies with diverse therapeutic mechanisms. The core clinical programs include romaciclib (RVU120), a first-in-class CDK8/19 inhibitor with multiple Phase II trials in hematologic malignancies (RIVER-81 for AML, POTAMI-61 for myelofibrosis, REMARK for LR-MDS), and dapolsertib (MEN1703), a dual PIM/FLT3 kinase inhibitor in Phase II for DLBCL. The preclinical pipeline features RVU305 (MTA-cooperative PRMT5 inhibitor) and early discovery programs in ADCs with novel payloads. Discovery capabilities include the ONCO Prime precision oncology platform for synthetic lethal target identification and the PERO platform for functional target validation.

Differentiator

Problem solved

Functional benefit

Brands

  • ONCO Prime: Precision oncology discovery platform leveraging patient-driven models, engineered systems, and high-throughput CRISPR/omics analytics for identification of synthetic lethal targets in genetically stratified cancers
  • PERO
  • ADCraft

Products and services

  • Romaciclib (RVU120)

Quantifiable outcome

  • 43% CR/CRi rate in RIVER-81 study at recommended dose of 150mg QD romaciclib + venetoclax
  • +4 more outcomes

Companies that use Ryvu

Customer profile

Named customers5 records

Segments8 records

Ideal customer profiles2 records

Ryvu technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Ryvu partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • BioNTechcoreStrategic or Co-development Partner · 16 March 2026Research collaboration and exclusive license option agreement originally disclosed in November 2022. In March 2026, the collaboration was extended by one year until November 2028. In September 2025, the collaboration was expanded to support BioNTech in accelerating site activation and patient enrollment for priority oncology clinical programs in Poland including lung, breast, and colorectal cancers. Ryvu supports BioNTech's clinical trials and is reimbursed for expenses with potential for milestone payments.
  • Children's Memorial Health InstituteminorStrategic or Co-development Partner · 1 September 2025Collaboration initiated September 2025 as part of MEDWAY project, an investigator-initiated Phase I clinical study evaluating romaciclib in combination with everolimus in children with recurrent or progressive medulloblastoma. First patient first visit expected Q2 2026.
  • Menarini GroupcoreStrategic or Co-development Partner · 26 March 2025JASPIS-01 Phase II study of dapolsertib (MEN1703/SEL24) for r/r DLBCL is fully funded by Menarini Group and operationally executed by Ryvu. First patient dosed March 2025.
  • ExelixiscoreOEM/ Whitelabel/ Licensing Partner · 28 September 2022Exclusive license agreement with Exelixis for STING ADC technology. Ryvu develops STING-based antibody-drug conjugates for targeted cancer therapy under this partnership.
  • EMSCOminorStrategic or Co-development PartnerPartnership for REMARK study - Phase II investigator-initiated trial of romaciclib in low-risk MDS. EMSCO provides funding and operational support.
  • BCUnitedminorStrategic or Co-development PartnerPartnership for RIVER-81 study in relapsed/refractory AML. BCUnited provides funding and operational support for clinical development.

Scale indicators16 records

Recent moves6 records

Expansion highlights4 records

Ryvu competitors and assessment

Company assessment

Direct peers

  • Werewolf Therapeutics: US clinical-stage oncology biotech developing conditionally activated therapeutics. Comparable as a small-cap clinical-stage oncology company with platform-driven pipeline development.
  • Bicycle Therapeutics: Clinical-stage UK biotech developing precision oncology therapeutics using bicyclic peptide technology. Comparable as a clinical-stage oncology company advancing novel modalities toward Phase II readouts with partnership revenue.
  • Foghorn Therapeutics: US clinical-stage oncology biotech targeting chromatin regulatory biology with small molecules. Comparable to Ryvu's transcriptional regulation focus and similar Phase II-stage portfolio profile.
  • Syros Pharmaceuticals: US clinical-stage precision oncology biotech using gene regulation platforms to develop small molecule therapies. Comparable in targeting transcriptional dysregulation and hematologic/oncology indications.
  • Tempest Therapeutics: US clinical-stage immuno-oncology biotech developing small molecule therapies. Comparable in scale, clinical stage, and oncology small molecule focus.
  • Kronos Bio: US clinical-stage oncology biotech developing small molecule therapies targeting dysregulated transcription and cell signaling. Closely comparable to Ryvu's CDK8/19 transcriptional regulation approach and Phase II hematology focus.
  • Aprea Therapeutics: US clinical-stage oncology biotech focused on small molecule therapeutics targeting DNA damage response and synthetic lethality. Directly comparable to Ryvu's synthetic lethality and DDR-adjacent pipeline.
  • BerGenBio: Norway-headquartered clinical-stage oncology biotech developing selective kinase inhibitors in hematologic and solid tumors. Highly comparable to Ryvu in size, stage, and kinase-targeting approach.

Broad incumbents

  • Schrödinger: US computational drug discovery platform serving multiple therapeutic areas including oncology. Broader and more established than Ryvu but relevant given overlapping computational/discovery approaches to small molecule design.

Emerging players

  • Recursion Pharmaceuticals: US AI-enabled drug discovery company developing pipeline across oncology and rare diseases. Comparable as a technology-driven drug discovery company, though with broader scope and larger capital base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ryvu social profiles

Digital presence

Ryvu financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ryvu leadership team

Management profile

Number of profiles

Profiles6 records

Ryvu funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ryvu M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ryvu

What does Ryvu do?

Ryvu Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel small molecule therapies targeting emerging oncology pathways, including CDK8/19, PIM/FLT3, and PRMT5. Its pipeline focuses on hematologic malignancies and selected solid tumors, with drug candidates advancing through preclinical and clinical stages (Phases 1 and 2). The company leverages proprietary discovery platforms to identify first-in-class therapeutic candidates for partnering or further development.

Is Ryvu a public or private company?

Ryvu is a public company. It is classified as public and is currently operating.

When was Ryvu founded?

Ryvu was founded in 2007. It employs 101 to 250 people.

Where is Ryvu based?

Ryvu is headquartered in Kraków, Poland, in the Europe region.

How does Ryvu make money?

Three revenue lines are on record. Partnership Revenue is the primary driver. The others are grant Funding and clinical Milestones.

Who are Ryvu's main competitors?

Direct peers on record are Werewolf Therapeutics, Bicycle Therapeutics, Foghorn Therapeutics, Syros Pharmaceuticals, Tempest Therapeutics, Kronos Bio, Aprea Therapeutics and BerGenBio. Schrödinger is listed as a broad incumbent. Recursion Pharmaceuticals is listed as an emerging player.

Does Ryvu have an API?

No public API is recorded for Ryvu.

What industry is Ryvu in?

Ryvu's product category is Clinical-Stage Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AktienDie Menarini Group und Ryvu Therapeutics geben auf der ASH-Jahrestagung 2026 die ersten klinischen Daten aus der Phase-II-Studie JASPIS-01 zu Dapolsertib (MEN1703, SEL24) bei stark vorbehandelten Patienten mit rezidiviertem/refraktärem aggressivem B-Zell-Menarini, Stemline, and Ryvu will present first clinical data from Phase-II study JASPIS-01 on Dapolsertib for heavily pre-treated patients with relapsed/refractory aggressive B-cell NHL at ASH 2026. The data show clinical efficacy in patients who had, on average, four prior therapy lines, including CAR-T and bispecific antibodies.PR NewswireDie Menarini Group und Ryvu Therapeutics geben auf der ASH-Jahrestagung 2026 die ersten klinischen Daten aus der Phase-II-Studie JASPIS-01 zu Dapolsertib (MEN1703, SEL24) bei stark vorbehandelten PatiMenarini, Stemline, and Ryvu will present first clinical data from the Phase II JASPIS-01 study on dapolsertib at ASH 2026. The data show clinical activity in heavily pretreated patients, with 53% having prior CAR-T and 60% having bispecific antibodies. The results will be presented on December 13, 2026.PRESSBEEEl Grupo Menarini y Ryvu Therapeutics presentan los primeros datos del estudio JASPIS-01 sobre dapolsertib ...Middle EastMenarini and Ryvu Therapeutics presented first clinical data of dapolsertib (MEN1703, SEL24) in B-cell NHL patients at ASH 2026. The phase II study JASPIS-01 targets patients with relapsed or refractory disease who have received prior therapy.PR NewswireEl Grupo Menarini y Ryvu Therapeutics presentan los primeros datos del estudio JASPIS-01 sobre dapolsertibMenarini and Ryvu Therapeutics will present first clinical data of dapolsertib in the ASH 2026 poster session. The phase II JASPIS-01 study showed clinical activity in patients who had received multiple prior treatments, including CAR-T and bispecific antibodies. The company expects to continue development based on these results.PR NewswireMenarini Group et Ryvu Therapeutics annoncent les premières données cliniques de l'étude de phase II JASPIS-01 sur le dapolsertib (MEN1703, SEL24)Menarini and Ryvu announced first clinical data of dapolsertib (MEN1703) in phase II JASPIS-01 for relapsed/refractory aggressive B-cell NHL at ASH 2026. The data showed clinical activity in heavily pre-treated patients, with 53% having prior CAR-T and 60% having bispecific antibodies. Results will be presented on December 13, 2026.PR Newswire APACMenarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual MeetingMenarini and Ryvu announced first clinical data from the Phase II JASPIS-01 study of dapolsertib in heavily pretreated relapsed/refractory aggressive B-cell non-Hodgkin lymphoma, to be presented at ASH 2026. The data showed clinical activity and a manageable safety profile, supporting continued development of the dual PIM/FLT3 inhibitor.AktienMenarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual MeetingMenarini and Ryvu announced first clinical data from the Phase II JASPIS-01 study of dapolsertib in heavily pretreated relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clinical activity was observed in patients with a median of four prior lines of therapy, including 53% prior CAR-T and 60% prior CD3×CD20 bispecifics. The data will be presented at the 2026 ASH Annual Meeting.PR NewswireMenarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-HodgMenarini and Ryvu announced first clinical data from the Phase II JASPIS-01 study of dapolsertib in heavily pretreated relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clinical activity was observed in patients with a median of four prior lines of therapy, including 53% who had received CAR-T cell therapy. The data will be presented at ASH 2026.NewswireMenarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual MeetingMenarini and Ryvu announced first clinical data from the Phase II JASPIS-01 study of dapolsertib in heavily pretreated relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clinical activity was observed in patients with a median of four prior lines of therapy, including 53% who had received CAR-T and 60% who had received CD3×CD20 bispecific antibodies. The data will be presented at the 2026 ASH Annual Meeting.PR NewswireMenarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-HodgMenarini and Ryvu announced first clinical data from the Phase II JASPIS-01 study of dapolsertib in heavily pretreated relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clinical activity was observed in patients with a median of four prior lines of therapy, including 53% who had received CAR-T cell therapy. The data will be presented at ASH 2026.